Bioncise NV

Cook MyoSite is a Pittsburgh-based biotechnology company specializing in muscle cell technology and regenerative medicine since 2002. The company develops and manufactures autologous muscle-derived cells (AMDC) and investigational cell therapies targeting muscle dysfunction disorders. Cook MyoSite's primary focus includes clinical development of iltamiocel for chronic fecal incontinence and AMDC for urinary sphincter repair, both advancing through clinical trials. Beyond clinical applications, the company supplies primary human skeletal muscle-derived cells and custom cell solutions to research institutions and pharmaceutical companies worldwide. Manufacturing operations maintain ISO 9001:2015 certification with rigorous quality standards. The company offers laboratory research services including custom cell culturing, cell characterization, and specialized muscle cell products optimized for research applications. With over 20 years of clinical development experience, Cook MyoSite provides highly characterized primary cells, cell culture media (MyoTonic), and expert technical support to advance regenerative medicine research and therapeutic development.